Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HRA Pharma
• Treatments: Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combination; Ethinyl estradiol, levonorgestrel drug combination; Levonorgestrel; Ulipristal acetate

Criteria

Inclusion Criteria:

• Healthy women aged 18-35 years old

• BMI < 30 Kg/m2

• Not at risk of pregnancy

• No use of progesterone-only-pill for 3 months before start of treatment cycle

• No use of implant hormonal contraception for 3 months before start of treatment cycle

• No use of levonorgestrel intrauterine system for 3 months before start of treatment cycle

• No use of depo provera for 12 months before start of treatment cycle

• Able to give informed consent.